Implementation of QbD strategies in the inoculum expansion of a mAb production process.

CHO PAT QbD inoculum expansion mAb

Journal

Engineering in life sciences
ISSN: 1618-0240
Titre abrégé: Eng Life Sci
Pays: Germany
ID NLM: 101193313

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 19 08 2020
revised: 12 11 2020
accepted: 12 11 2020
entrez: 15 3 2021
pubmed: 16 3 2021
medline: 16 3 2021
Statut: epublish

Résumé

The quality by design approach was introduced to the biopharmaceutical industry over 15 years ago. This principle is widely implemented in the characterization of monoclonal antibody production processes. Anyway, the early process phase, namely the inoculum expansion, was not yet investigated and characterized for most processes. In order to increase the understanding of early process parameter interactions and their influence on the later production process, a risk assessment followed by a design of experiments approach was conducted. The DoE included the critical parameters methotrexate (MTX) concentration, initial passage viable cell density and passage duration. Multivariate data analysis led to mathematical regression models and the establishment of a designated design space for the studied parameters. It was found that the passage duration as well as the initial viable cell density for each passage during the inoculum expansion have severe effects on the growth rate and viability of the early process phase. Furthermore, the variations during the inoculum expansion directly influenced the production process responses. This carry-over of factor effects highlights the crucial impact of early process failures and the importance of process analysis and control during the first part of mAb production processes.

Identifiants

pubmed: 33716618
doi: 10.1002/elsc.202000056
pii: ELSC1354
pmc: PMC7923587
doi:

Types de publication

Journal Article

Langues

eng

Pagination

196-207

Informations de copyright

© 2020 The Authors. Engineering in Life Sciences published by Wiley‐VCH GmbH.

Déclaration de conflit d'intérêts

We confirm that all corresponding authors agree with the submission and publication of this paper and that there is no conflict of interest concerning financial and personal relationships. The manuscript does not contain neither experiments using animals nor human studies. Furthermore, we confirm that the article has not been published previously by any of the authors and is not under consideration for publication elsewhere at the time of submission.

Références

Biotechnol Bioeng. 2010 Aug 15;106(6):894-905
pubmed: 20589669
Eng Life Sci. 2019 Mar 14;19(5):341-351
pubmed: 32625013
Biotechnol Prog. 2019 Mar;35(2):e2757
pubmed: 30479066
J Pharm Sci. 2013 Dec;102(12):4274-83
pubmed: 24122699
Mol Cell Endocrinol. 1992 Feb;83(2-3):153-71
pubmed: 1547909
Nat Biotechnol. 2009 Jan;27(1):26-34
pubmed: 19131992
Bioprocess Biosyst Eng. 2020 Feb;43(2):193-205
pubmed: 31549309
Biotechnol Prog. 2006 May-Jun;22(3):696-703
pubmed: 16739951
Trends Biotechnol. 2009 Sep;27(9):546-53
pubmed: 19647883
Asian J Pharm Sci. 2017 Jan;12(1):1-8
pubmed: 32104308
AAPS J. 2014 Jul;16(4):771-83
pubmed: 24854893

Auteurs

Ole Jacob Böhl (OJ)

Leibniz Universität Hannover Institut für Technische Chemie Hannover Germany.

Jana Schellenberg (J)

Leibniz Universität Hannover Institut für Technische Chemie Hannover Germany.

Janina Bahnemann (J)

Leibniz Universität Hannover Institut für Technische Chemie Hannover Germany.

Bernd Hitzmann (B)

Universität Hohenheim Fachgebiet für Prozessanalytik und Getreidewissenschaft Stuttgart Germany.

Thomas Scheper (T)

Leibniz Universität Hannover Institut für Technische Chemie Hannover Germany.

Dörte Solle (D)

Leibniz Universität Hannover Institut für Technische Chemie Hannover Germany.

Classifications MeSH